Journal of Antimicrobial Chemotherapy (2001) 47, 655-658
© 2001 The British Society for Antimicrobial Chemotherapy
Brief report |
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones
a Department of Microbiology, f School of Professional and Continuing Education, The University of Hong Kong; b Department of Microbiology, Queen Mary Hospital; c Department of Clinical Pathology, Tuen Mun Hospital; d Department of Clinical Pathology, Queen Elizabeth Hospital; e Department of Clinical Pathology, Princess Margaret Hospital, Hong Kong SAR, China
Ciprofloxacin-susceptible (n = 7) and -resistant (MIC 
4 mg/L) (n = 15) clinical isolates of Streptococcus pneumoniae from diverse sources in Hong Kong were studied for target site modifications and efflux phenotype. Reserpine-inhibited efflux of ciprofloxacin and/or levofloxacin was common in both susceptible and non-susceptible isolates. The ParC substitutions K137N and/or S79F or Y were associated with increased ciprofloxacin MICs. The GyrA substitution S81F was only found in isolates with full resistance to ciprofloxacin (MIC 16 mg/L) and levofloxacin (MIC 8 mg/L). Among clinical isolates of S. pneumoniae, accumulation of target site mutations in strains with an efflux mechanism was associated with increasing MICs of fluoroquinolones.
* Correspondence address. Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong SAR, China. Tel: +852-2855-4897; Fax: +852-2855-1241; E-mail: plho{at}hkucc.hku.hk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. J. Christiansen, J. M. Bell, J. D. Turnidge, and R. N. Jones Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001 Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2049 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Canton, M. Morosini, M. C. Enright, and I. Morrissey Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme J. Antimicrob. Chemother., December 1, 2003; 52(6): 944 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials Ann. Pharmacother., October 1, 2003; 37(10): 1478 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models Ann. Pharmacother., September 1, 2003; 37(9): 1287 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-W. Decousser, P. Pina, F. Picot, C. Delalande, B. Pangon, P. Courvalin, P. Allouch, and the ColBVH study group Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey J. Antimicrob. Chemother., May 1, 2003; 51(5): 1213 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Morrissey, D. J. Farrell, S. Bakker, S. Buckridge, and D. Felmingham Molecular Characterization and Antimicrobial Susceptibility of Fluoroquinolone-Resistant or -Susceptible Streptococcus pneumoniae from Hong Kong Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1433 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Ho, R. W. H. Yung, D. N. C. Tsang, T. L. Que, M. Ho, W. H. Seto, T. K. Ng, W. C. Yam, and W. W. S. Ng Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000 J. Antimicrob. Chemother., November 1, 2001; 48(5): 659 - 665. [Abstract] [Full Text] [PDF]
|
|